Head-to-head evidence
CID-103 vs Isatuximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
CID-103
Developed by CASI Pharmaceuticals, Inc.
NCT04758767 · Phase 1 · completed
All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Isatuximab
Marketed by Sanofi
NCT02990338 · Phase 3 · completed
Participants were randomized 1:1 to isatuximab plus pomalidomide and dexamethasone or pomalidomide and dexamethasone alone, but the study was open-label rather than double-blind. The primary clinical endpoint, progression-free survival, was met: median survival was 11.53 versus 6.47 months, with a hazard ratio of 0.596 and p=0.0005.
Next expected readout: November 2026 · NCT06517017 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CID-103's landscape · Isatuximab's landscape